CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Affiliations

• ¹ Department of Medical Oncology, Ospedale Policlinico San Martino, Genova, Italy.
• ² Unit of Clinical Epidemiology, Ospedale Policlinico San Martino, Genova, Italy.
• ³ Unit of Tumor Epigenetics, Ospedale Policlinico San Martino, Genova, Italy.
• ⁴ Unit of Tumor Epigenetics, Ospedale Policlinico San Martino, Genova, Italy; Department of Health Sciences, University of Genova, Italy.
• ⁵ Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy.
• ⁶ Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
• ⁷ Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy.
• ⁸ Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy; Medical Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
• ⁹ Department of Medical Oncology and Molecular Genetics Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
• ¹⁰ Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
• ¹¹ Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
• ¹² Section of Surgical Pathology, Department of Medical Sciences, University of Turin, Turin, Italy.
• ¹³ Immunotherapy and Cell Therapy, IRCCS-IRST, Meldola, Italy.
• ¹⁴ Endocrinology Unit, Department of Internal Medicine (DiMI), University of Genova, Italy.
• ¹⁵ Unit of Tumor Epigenetics, Ospedale Policlinico San Martino, Genova, Italy. Electronic address: mariapia.pistillo@hsanmartino.it.